Effect of Transcutaneous Vagus Nerve Stimulation for Pain Control After Cesarean Delivery
Effect of Non-invasive Transcutaneous Vagus Nerve Stimulation for Pain Control After Cesarean Delivery - a Randomised Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yingjie Du
- Phone Number: +86 18601903288
- Email: duyingjiemazui@163.com
Study Locations
-
-
-
Beijing, China, 100730
- Beijing Tongren Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients are classified as American Society of Anesthesiologists (ASA) physical status I to III.
- Scheduled for elective cesarean delivery under spinal anesthesia.
- Patients are aged between 19 to 45 years old.
- Patients have provided written informed consent.
Exclusion Criteria:
- Local skin infection occurs in the auricular area during transcutaneous auricular vagus nerve stimulation.
- Cases where spinal anesthesia fails and general anesthesia is required.
- Patients with conditions such as recurrent alcohol abuse, fever, convulsions, or cardiopulmonary failure.
- Patients who have used opioid medications at least 6 months prior to surgery.
- Patients who are unable to understand the consent form and study questionnaire, including those with cognitive impairments.
- Patients with a history of psychiatric illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Transcutaneous auricular vagus nerve stimulation (taVNS)
Bilateral auricle area is selected, where the branches of the vagus nerve are abundantly distributed.
The use of an SDZ-IIB electronic acupuncture therapy device and specially designed ear clips to stimulate both sides for 30 minutes each session.
The stimulation parameters are set to sparse dense wave, with a frequency of 4 Hz/20 Hz, and the intensity is adjusted based on the patient's tolerance, gradually increasing from 0 to the highest point the patient can tolerate.
A total of two stimulations are administered, the first immediately after the baby is delivered, and the second is 23.5 hours postoperative.
|
Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
|
|
Sham Comparator: Sham transcutaneous auricular vagus nerve stimulation (s-taVNS)
Bilateral auricular areas are selected, where the branches of the vagus nerve are abundantly distributed.
An SDZ-IIB electronic acupuncture therapy device and specially designed ear clips are used to stimulate both sides.
The stimulation parameters are set to sparse dense waves, with a frequency of 4 Hz/20 Hz, and the intensity is adjusted based on the patient's tolerance, gradually increasing from 0 to the highest level the patient can endure, then the device is then turned off, electric current stimulation is applied for approximately 10 seconds.
The process of attaching the clip to the earlasts for 30 minutes.
A total of two stimulations are administered, the first immediately after the baby is delivered, and the second 23.5 hours postoperatively.
|
Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numeric Rating Scale (NRS-11) pain score during movement
Time Frame: 24 hours postoperatively
|
Numeric Rating Scale (NRS-11), this scale is a validated tool for measuring pain intensity, with scores ranging from 0 (no pain) to 10 (the most severe pain imaginable).The higher the score, the more severe the pain.
|
24 hours postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
C-reactive protein (CRP)
Time Frame: 48 hours postoperatively
|
Serum CRP concentration.
|
48 hours postoperatively
|
|
NFκB
Time Frame: 48 hours postoperatively
|
Serum NFκB concentration.
|
48 hours postoperatively
|
|
Postoperative adverse reactions
Time Frame: From date of randomization until the date of discharge, assessed up to 7 days
|
Explore whether taVNS intervention increases postoperative adverse reactions, including dizziness, bloating, itching and so on.
|
From date of randomization until the date of discharge, assessed up to 7 days
|
|
Postoperative severe complications
Time Frame: From date of randomization until the date of discharge, assessed up to 7 days
|
Postoperative severe complications, including pulmonary complications, liver function abnormalities, heart function abnormalities, kidney function abnormalities, and SIRS (Systemic Inflammatory Response Syndrome).
|
From date of randomization until the date of discharge, assessed up to 7 days
|
|
the proportion of patients with NRS pain score > 6
Time Frame: 24 hours postoperatively
|
Assess the proportion of severe pain by calculating the ratio of NRS pain scores that are greater than 6.
|
24 hours postoperatively
|
|
Epinephrine
Time Frame: 48 hours postoperatively
|
Serum Epinephrine concentration.
|
48 hours postoperatively
|
|
aEP
Time Frame: 48 hours postoperatively
|
Serum aEP concentration
|
48 hours postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Guyan Wang, Beijing Tongren Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TREC2024-KY089.R1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.